Identifying cancer prognosis genes through causal learning.

Brief Bioinform

School of Artificial Intelligence, Jilin University, 3003 Qianjin Street, 130012 Changchun, China.

Published: November 2024

Accurate identification of causal genes for cancer prognosis is critical for estimating disease progression and guiding treatment interventions. In this study, we propose CPCG (Cancer Prognosis's Causal Gene), a two-stage framework identifying gene sets causally associated with patient prognosis across diverse cancer types using transcriptomic data. Initially, an ensemble approach models gene expression's impact on survival with parametric and semiparametric hazard models. Subsequently, an iterative conditional independence test combined with graph pruning is utilized to infer the causal skeleton, thereby pinpointing prognosis-related genes. Experiments on transcriptomic data from 18 cancer types sourced from The Cancer Genome Atlas Project demonstrate CPCG's effectiveness in predicting prognosis under four evaluation metrics. Validations on 24 additional datasets covering 12 cancer types from the Gene Expression Omnibus and the Chinese Glioma Genome Atlas Project further demonstrate CPCG's robustness and generalizability. CPCG identifies a concise but reliable set of genes, obviating the need for gene combination enumeration for survival time estimation. These genes are also proved closely linked to crucial biological processes in cancer. Moreover, CPCG constructs a stable causal skeleton and exhibits insensitivity to the order of data shuffling. Overall, CPCG is a powerful tool for extracting cancer prognostic biomarkers, offering interpretability, generalizability, and robustness. CPCG holds promise for facilitating targeted interventions in clinical treatment strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729728PMC
http://dx.doi.org/10.1093/bib/bbae721DOI Listing

Publication Analysis

Top Keywords

cancer types
12
cancer prognosis
8
cancer
8
transcriptomic data
8
causal skeleton
8
genome atlas
8
atlas project
8
project demonstrate
8
demonstrate cpcg's
8
genes
5

Similar Publications

A pan-cancer analysis: predictive role of ZNF32 in cancer prognosis and immunotherapy response.

Discov Oncol

January 2025

Department of Otolaryngology-Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

The zinc finger protein 32 (ZNF32) has been associated with high expression in various cancers, underscoring its significant function in both cancer biology and immune response. To further elucidate the biological role of ZNF32 and identify potential immunotherapy targets in cancer, we conducted an in-depth analysis of ZNF32. We comprehensively investigated the expression of ZNF32 across tumors using diverse databases, including TCGA, CCLE, TIMER2.

View Article and Find Full Text PDF

Introduction: Around 85% of non-small cell lung cancers (NSCLCs) are diagnosed at an advanced stage (IIIB to IV), where therapeutic options depend on molecular analysis. However, diagnostic material for molecular testing is often represented by cytological samples which are generally scarce and span a wide range of preparation types. Thus, the primary objective is to efficiently manage materials for molecular profiling.

View Article and Find Full Text PDF

Facile integration of a binary nano-prodrug with αPD-L1 as a translatable technology for potent immunotherapy of TNBC.

Acta Biomater

January 2025

Hengyang Medical School, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, MOE Key Lab of Rare Pediatric Disease, University of South China, Hengyang 421001, China. Electronic address:

Immune checkpoint blockers (ICBs)-based immunotherapy is a favorable approach for efficient triple-negative breast cancer (TNBC) treatment. However, the therapeutic efficacy of ICBs is greatly compromised by immunosuppressive tumor microenvironments (TMEs) and low expression levels of programmed cell death ligand-1 (PD-L1). Herein, we constructed an amphiphilic prodrug by linking a hydrophobic STING agonist, MSA-2 and a hydrophilic chemotherapeutic drug, gemcitabine (GEM) via an ester bond, which can self-assemble into GEM-MSA-2 (G-M) nanoparticles (NPs) with a tumor growth inhibition (TGI) value of 87.

View Article and Find Full Text PDF

Advances in RNA editing in hematopoiesis and associated malignancies.

Blood

January 2025

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Center for Stem Cell Medicine,, Tianjin, China.

Adenosine-to-inosine (A-to-I) RNA editing is a prevalent RNA modification essential for cell survival. The process is catalyzed by the Adenosine Deaminase Acting on RNA (ADAR) enzyme family that converts adenosines in double-stranded RNAs (dsRNAs) into inosines, which are read as guanosines during translation. Deep sequencing has helped to reveal that A-to-I editing occurs across various types of RNAs to affect their functions.

View Article and Find Full Text PDF

Background: The results of many large randomized clinical trials (RCTs) have transformed clinical practice in gastroesophageal reflux disease (GERD) and esophageal hiatal hernia (HH). However, research waste (i.e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!